Bisphosphonate‐enoxacin inhibit osteoclast formation and function by abrogating RANKL‐induced JNK signalling pathways during osteoporosis treatment

Osteoporosis is an age‐related disease characterized by low mineral density, compromised bone strength and increased risk of fragility fracture. Most agents for treating osteoporosis focus primarily on anti‐resorption by inhibiting osteoclast activity. Bisphosphonate (BP) is a potent anti‐resorptive...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Qiang, Zhan, Ping, Li, Xiaofeng, Mo, Fengbo, Xu, Huaen, Liu, Yuan, Lai, Qi, Zhang, Bin, Dai, Min, Liu, Xuqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572771/
https://www.ncbi.nlm.nih.gov/pubmed/34651433
http://dx.doi.org/10.1111/jcmm.16949

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572771/
https://www.ncbi.nlm.nih.gov/pubmed/34651433
http://dx.doi.org/10.1111/jcmm.16949

Ejemplares similares